STOCK TITAN

Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Eyenovia, Inc. (NASDAQ: EYEN) will release its third-quarter financial results for 2022 on November 10, 2022, after market close. Following this, the company's management will hold a conference call at 4:30 PM ET to discuss the results. Participants can join via phone or a live webcast on the company's investor relations website. Eyenovia focuses on developing ophthalmic therapeutic solutions, specifically using its Optejet® delivery system for microdose array print therapeutics aimed at conditions like mydriasis and presbyopia.

Positive
  • None.
Negative
  • None.

Company to host an investor conference call and webcast at 4:30pm ET on that day

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced that the Company will release financial results for the third quarter ended September 30, 2022 on Thursday, November 10, 2022, after the markets close. Following the release, Eyenovia management will host a conference call to review the financial and operating results.

The conference call is scheduled to begin at 4:30pm ET on Thursday, November 10, 2022. Participants should dial 1-866-575-6539 (domestic) or 1-929-477-0448 (international) with the conference code 1600616. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit www.eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com


FAQ

When will Eyenovia release its Q3 2022 financial results?

Eyenovia will release its Q3 2022 financial results on November 10, 2022.

What time is Eyenovia's investor conference call?

The investor conference call is scheduled for 4:30 PM ET on November 10, 2022.

How can I access Eyenovia's conference call?

You can access Eyenovia's conference call by dialing 1-866-575-6539 for domestic calls or 1-929-477-0448 for international calls, using conference code 1600616. A live webcast is also available on their website.

What does Eyenovia focus on developing?

Eyenovia focuses on developing ophthalmic therapeutics, particularly microdosed medications for conditions such as mydriasis and presbyopia.

Eyenovia, Inc.

NASDAQ:EYEN

EYEN Rankings

EYEN Latest News

EYEN Stock Data

9.43M
110.07M
9.99%
13.73%
2.49%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK